Epigenetic markers could point to type 1 diabetes risk; Gene discovery indicates osteoporosis risk;

> New biomarker tests could provide an alternative to biopsies to track disease in patients with lupus. Release

> Fecal biomarkers of inflammation could beat a path to new diagnostics and ways of caring for patients with inflammatory bowel disease, according to experts from the Sydney Children's Hospital in Australia. Abstract

> Scientists discover that epigenetic clues could become important markers for type 1 diabetes risk and point to new non-genetic underpinnings of the metabolic disorder. Article

> A new gene discovery could provide a marker determining a patient's risk for osteoporosis. Release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.